Company profile

Immunai Technologies

Immunai Technologies, founded in 2018 and headquartered in the United States, has raised about $295 million in funding, including a $215 million Series B round in October 2021 led by Koch Disruptive Technologies, valuing it near $1 billion. The company develops the AMICA platform - an annotated multi‑omic immune cell atlas combined with AI and functional genomics - to decode the immune system and speed discovery of immunomodulatory therapeutics. With investors like Catalio Capital and Alexandria Venture Investments, Immunai is positioned at the forefront of precision immunology and therapeutic innovation.

Back to profiles

Quick facts

Total funding: $295 million
Founded: 2018

Notable investors

Koch Disruptive Technologies

Reach buyers like Immunai Technologies on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Immunai Technologies
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Immunai Technologies.

The 14-day trial ships every feature, no card required.

Start free →